Bridgebio Pharma Stock Working Capital
| BBIO Stock | USD 27.49 1.05 3.97% |
BridgeBio Pharma fundamentals help investors to digest information that contributes to BridgeBio Pharma's financial success or failures. It also enables traders to predict the movement of BridgeBio Stock. The fundamental analysis module provides a way to measure BridgeBio Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BridgeBio Pharma stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 333.7 M | 469.5 M | |
| Change In Working Capital | 5.1 M | 8.9 M |
BridgeBio | Working Capital |
BridgeBio Pharma Company Working Capital Analysis
BridgeBio Pharma's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current BridgeBio Pharma Working Capital | 333.75 M |
Most of BridgeBio Pharma's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BridgeBio Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
BridgeBio Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for BridgeBio Pharma is extremely important. It helps to project a fair market value of BridgeBio Stock properly, considering its historical fundamentals such as Working Capital. Since BridgeBio Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BridgeBio Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BridgeBio Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
BridgeBio Net Invested Capital
Net Invested Capital |
|
In accordance with the company's disclosures, BridgeBio Pharma has a Working Capital of 333.75 M. This is 21.59% lower than that of the Biotechnology sector and 38.04% lower than that of the Health Care industry. The working capital for all United States stocks is 77.42% higher than that of the company.
BridgeBio Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BridgeBio Pharma's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BridgeBio Pharma could also be used in its relative valuation, which is a method of valuing BridgeBio Pharma by comparing valuation metrics of similar companies.BridgeBio Pharma is currently under evaluation in working capital category among its peers.
BridgeBio Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of BridgeBio Pharma from analyzing BridgeBio Pharma's financial statements. These drivers represent accounts that assess BridgeBio Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of BridgeBio Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 3.7B | 8.4B | 2.4B | 1.1B | 6.6B | 6.9B | |
| Enterprise Value | 3.4B | 8.5B | 3.7B | 2.5B | 7.9B | 8.3B |
BridgeBio Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, BridgeBio Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BridgeBio Pharma's managers, analysts, and investors.Environmental | Governance | Social |
BridgeBio Fundamentals
| Return On Equity | -17.9 | ||||
| Return On Asset | -0.49 | ||||
| Profit Margin | (2.02) % | ||||
| Operating Margin | (68.50) % | ||||
| Current Valuation | 6.46 B | ||||
| Shares Outstanding | 188.99 M | ||||
| Shares Owned By Insiders | 5.39 % | ||||
| Shares Owned By Institutions | 94.45 % | ||||
| Number Of Shares Shorted | 17.19 M | ||||
| Price To Earning | (13.72) X | ||||
| Price To Book | 123.68 X | ||||
| Price To Sales | 23.86 X | ||||
| Revenue | 9.3 M | ||||
| Gross Profit | 74.21 M | ||||
| EBITDA | (565.47 M) | ||||
| Net Income | (643.2 M) | ||||
| Cash And Equivalents | 715.71 M | ||||
| Cash Per Share | 4.83 X | ||||
| Total Debt | 1.74 B | ||||
| Debt To Equity | 4.61 % | ||||
| Current Ratio | 5.46 X | ||||
| Book Value Per Share | (6.51) X | ||||
| Cash Flow From Operations | (527.72 M) | ||||
| Short Ratio | 10.85 X | ||||
| Earnings Per Share | (2.42) X | ||||
| Price To Earnings To Growth | 0.05 X | ||||
| Target Price | 48.53 | ||||
| Number Of Employees | 550 | ||||
| Beta | 1.09 | ||||
| Market Capitalization | 5.2 B | ||||
| Total Asset | 546.38 M | ||||
| Retained Earnings | (2.56 B) | ||||
| Working Capital | 333.75 M | ||||
| Current Asset | 513.67 M | ||||
| Current Liabilities | 51.37 M | ||||
| Net Asset | 546.38 M |
About BridgeBio Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BridgeBio Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BridgeBio Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BridgeBio Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with BridgeBio Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BridgeBio Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BridgeBio Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against BridgeBio Stock
| 0.46 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.35 | OPT | Opthea | PairCorr |
| 0.35 | NAMS | NewAmsterdam Pharma | PairCorr |
The ability to find closely correlated positions to BridgeBio Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BridgeBio Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BridgeBio Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BridgeBio Pharma to buy it.
The correlation of BridgeBio Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BridgeBio Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BridgeBio Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BridgeBio Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out BridgeBio Pharma Piotroski F Score and BridgeBio Pharma Altman Z Score analysis. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 1.194 | Quarterly Revenue Growth (0.33) | Return On Assets (0.49) | Return On Equity (17.90) |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.